Studies on the age dependent changes in serum adenosine deaminase activity and its changes in hepatitis

Vasudha, K.; Kumar, Arun; Venkatesh, Talavara

doi:10.1007/bf02913078

Cited by 9 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has been demonstrated that the presence of these isoenzymes in serum, regardless of their amount, has a diagnostic value. Previous studies found the elevated activity of ADA2 in a variety of conditions such as acquired immunodeWciency syndrome (AIDS), T-cell lymphoblastic malignancies, tuberculosis, liver diseases, rheumatoid arthritis, and myasthenia gravis (MG) [6,[8][9][10][11][12][13][14]. We have recently reported the similar data for primary immunodeWciency disorders (PIDs) [7].…”

Section: Introductionsupporting

confidence: 53%

See 1 more Smart Citation

Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern

et al. 2011

View full text Add to dashboard Cite

Adenosine deaminase (ADA) plays a crucial role in the development and maintenance of normal immune system. So, any immunological imbalances could associate with its altered activity in serum. This study evaluated the activity of total ADA and its isoenzymes in serum of 45 patients with systemic lupus erythematosus (SLE). Included were 23 patients with active SLE, 22 during the inactive phase of the disease, and 45 healthy subjects. Our results provided evidence that the significantly elevated total ADA activity in serum of SLE patients is correlated mainly with the increased ADA2 level. The highest mean ADA2 activity during the relapse phase of the disease could be an indication to the macrophages, the main source of ADA2. It might be concluded that ADA and its isoenzymes analysis in serum of patients could be used as a useful and non-invasive diagnostic tool in evaluation of SLE active phase and the disease severity.

show abstract

Section: Introductionsupporting

confidence: 53%

“…They are traditionally divided into organ-speciWc and non-organ-speciWc disorders [12]. Systemic lupus erythematosus (SLE) appears to be a prototypic example of the latter, whose manifestations associate with the production of a plethora of autoantibodies, mostly against nucleus DNA.…”

Section: Introductionmentioning

confidence: 99%

Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A possible explanation is the lack of age-matched validation cohort. Age-dependent serum adenosine deaminase activity may have had an impact on this result [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC

et al. 2018

View full text Add to dashboard Cite

BackgroundIdiopathic pulmonary fibrosis (IPF) is a lethal lung disease of unknown etiology. Patients present loss of lung function, dyspnea and dry cough. Diagnosis requires compatible radiologic imaging and, in undetermined cases, invasive procedures such as bronchoscopy and surgical lung biopsy. The pathophysiological mechanisms of IPF are not completely understood. Lung injury with abnormal alveolar epithelial repair is thought to be a major cause for activation of profibrotic pathways in IPF. Metabolic signatures might indicate pathological pathways involved in disease development and progression. Reliable serum biomarker would help to improve both diagnostic approach and monitoring of drug effects.MethodThe global metabolic profiles measured by ultra high-performance liquid chromatography coupled to high-resolution mass spectrometry (UHPLC-HRMS) of ten stable IPF patients were compared to the ones of ten healthy participants. The results were validated in an additional study of eleven IPF patients and ten healthy controls.ResultsWe discovered 10 discriminative metabolic features using multivariate and univariate statistical analysis. Among them, we identified one metabolite at a retention time of 9.59 min that was two times more abundant in the serum of IPF patients compared to healthy participants. Based on its ion pattern, a lysophosphatidylcholine (LysoPC) was proposed. LysoPC is a precursor of lysophosphatidic acid (LPA) – a known mediator for lung fibrosis with its pathway currently being evaluated as new therapeutic drug target for IPF and other fibrotic diseases.ConclusionsWe identified a LysoPC by UHPLC-HRMS as potential biomarker in serum of patients with IPF. Further validation studies in a larger cohort are necessary to determine its role in IPF.Trial RegistrationSerum samples from IPF patients have been obtained within the clinical trial NCT02173145 at baseline and from the idiopathic interstitial pneumonia (IIP) cohort study. The study was approved by the Swiss Ethics Committee, Bern (KEK 002/14 and 246/15 or PB_2016–01524).Electronic supplementary materialThe online version of this article (doi: 10.1186/s12931-018-0714-2) contains supplementary material, which is available to authorized users.

show abstract

“…In addition, since the average ALT level for six of seven patients was Ͻ40 U/liter but Ͼ20 U/liter, these results illustrate the occurrence of host immune selection even with a slight increase in average ALT level. Although the cutoff of 20 U/liter may seem arbitrary, the ALT levels of hepatitis-free populations of different age groups have never exceeded this level (13,41). To this extent, an ALT level of 20 U/liter may represent the action of host immunity against HBV.…”

Section: Discussionmentioning

confidence: 99%

Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases

Wang

Chien

Huang

et al. 2010

J Virol

View full text Add to dashboard Cite

Little is known about hepatitis B virus (HBV) diversity changes within a host during the immunotolerant phase of chronic HBV infection. Such knowledge, nevertheless, may help in understanding how host immunity and HBV interact at the early stage of infection. In this study, serial serum samples were collected from a long-term (>17 years) follow-up cohort of seven patients, and multiple copies of the full-length viral genome from serially sampled sera were recovered and analyzed. Viral genetic diversity was positively correlated with host immunity, represented by levels of alanine aminotransferase (ALT), but was negatively correlated with the viral copy number. During the immunotolerant phase, when the host immunity was feeble (ALT < 20 U/liter), viral nucleotide diversity decreased while copy numbers increased. Rates of evolutionary change derived for different patients were in a very narrow range (1.6 ؋ 10 ؊5 to 5.4 ؋ 10 ؊5 /site/year). As the disease progressed toward the immunoclearance phase (ALT > 20 U/liter), viral diversity increased but copy numbers decreased. Evolutionary rates varied among patients in accordance with their levels of ALT, ranging from 9.6 ؋ 10 ؊6 to 3.2 ؋ 10 ؊4 /site/year. More than half (19/32 sites) of positively selected sites resided in immune epitopes, suggesting their possible role in host immunity. Our results demonstrate that host immunity is a dominant factor in HBV evolution. Different selective forces, including immune-mediated positive selection and virus-mediated negative selection, operate in tandem in shaping viral population dynamics within a host.

show abstract

Studies on the age dependent changes in serum adenosine deaminase activity and its changes in hepatitis

Cited by 9 publications

References 12 publications

Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern

Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern

Serum metabolic profiling identified a distinct metabolic signature in patients with idiopathic pulmonary fibrosis – a potential biomarker role for LysoPC

Distinct Hepatitis B Virus Dynamics in the Immunotolerant and Early Immunoclearance Phases

Contact Info

Product

Resources

About